The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 14 of the 40 sources its claims cite were checked for support.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Open accessAbstract
BACKGROUND: Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group). The primary end point was progression-free survival. RESULTS: white cells), as compared with 4.6% of those in the control group (P<0.001); results below the threshold for minimal residual disease were associated with improved outcomes. The most common adverse events of grade 3 or 4 during treatment were neutropenia (in 51.9% of the patients in the daratumumab group vs. 37.0% of those in the control group), thrombocytopenia (in 12.7% vs. 13.5%), and anemia (in 12.4% vs. 19.6%). Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2. CONCLUSIONS: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma. Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy. (Funded by Janssen Research and Development; POLLUX ClinicalTrials.gov number, NCT02076009 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 of 40 cited sources checked · 9 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, this category of minimal residual disease status has not been examined to date in patients with relapsed or refractory multiple myeloma, in part because of limited availability of data showing a correlation between depth of response and survival outcomes in patients at this stage of the disease.7”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The “Relapsed and/or refractory” section (page unavailable) says data linking depth of response to outcomes are limited, supporting the citing sentence’s rationale. The “Redefining CR” section discusses minimal residual disease (MRD) studies in newly diagnosed patients, but does not state that MRD status had never been examined in relapsed or refractory patients. The relapsed-setting section’s “MR” means minimal response, not minimal residual disease. (LLM, conf=0.78)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As in our trial (POLLUX), the addition of daratumumab to a standard-of-care regimen of bortezomib and dexamethasone in the CASTOR trial was associated with a significantly lower risk of disease progression or death.18”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
What the sources say
- Supportedcites [18] source
The Trial Treatments section (p. 3) confirms that CASTOR compared daratumumab plus bortezomib and dexamethasone with bortezomib and dexamethasone alone. The Discussion (p. 11) reports significantly longer progression-free survival and a 61.4% lower risk of disease progression or death in the daratumumab group. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
What the sources say
- Not checked — no full text of the sourcecites [27] source
- Supportedcites [28] source
The Safety section identifies thrombocytopenia, gastrointestinal events, and rash as adverse events observed with lenalidomide-dexamethasone, and describes management of gastrointestinal events with supportive therapy and dose adjustment. This supports the part of the sentence attributed to this paper: the known toxic effects of lenalidomide-dexamethasone. The daratumumab-specific part has separate citations and is not attributed to this source. (LLM, conf=0.90)
- Supportedcites [30] source
This citation is attached to the known toxic effects of lenalidomide and dexamethasone, not to the daratumumab-specific part of the sentence. The Randomization and Study Treatment section identifies a lenalidomide–dexamethasone control group, and the Safety section and Table 3 report its adverse events. The paper does not assess the daratumumab combination. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [31] source
- Not checked — no full text of the sourcecites [9] source
- Supportedcites [10] source
This source is cited for the known toxic effects of daratumumab, not for the safety of the three-drug combination. The Safety section (p. 5) reports that most adverse events with daratumumab were grade 1 or 2, and the Discussion (p. 11) describes an acceptable safety profile and mostly mild infusion-related reactions. (LLM, conf=0.89)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar results were observed in the intentionto-treat population (Table S3 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consistent with the higher rates of deeper responses in the daratumumab group, the rate of results below the threshold for minimal residual disease was significantly higher in the daratumumab group than in the control group (by 3 to 5 times) at all evaluated thresholds (1 tumor cell per 10 4 , 10 5 , and 10 6 white cells) (Fig. S4 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At the interim analysis, a total of 75 deaths had been observed (30 patients in the daratumumab group and 45 in the control group) (Table S4 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A significantly higher rate of overall response was observed in the daratumumab group than in the control group (92.9% vs. 76.4%,P<0.001), as was a higher rate of complete response or better (43.1% vs. 19.2%,P<0.001).”
- Also stated in: § Efficacy · plain
“the rate of complete response or better (43.1% vs. 19.2%,P<0.001).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Efficacy · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Progression-free survival was similarly prolonged in the daratumumab group among patients who had previous exposure to lenalidomide and those who had no previous exposure, as compared with the control group (Fig. S3 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median progression-free survival was not reached (95% CI, could not be estimated) in the daratumumab group, as compared with 18.4 months (95% CI, 13.9 to could not be estimated) in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with a partial response or better, the rate of progression-free survival at 12 months was 87.8% (95% CI, 83.1 to 91.3) in the daratumumab group versus 73.6% (95% CI, 67.0 to 79.1) in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Daratumumab, a human IgGκ monoclonal antibody that targets CD38, 8 has shown substantial single-agent efficacy and a manageable safety profile in phase 1-2 studies involving patients with heavily pretreated relapsed or refractory multiple myeloma, with reported overall response rates of 29% and 36%.9,10”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Supportedcites [8] source
The Ab generation section states that all antibodies described, including daratumumab, were human IgG1, κ antibodies. The Discussion identifies daratumumab as a human IgG1 antibody that binds CD38. The later phase 1–2 efficacy claims carry separate citations and are not attributed to this source. (LLM, conf=0.94)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point was progression-free survival, with progression determined with the use of a validated computer algorithm that combined laboratory results (e.g., M-protein level) and applicable imaging and generated the outcome according to IMWG criteria (see the Supplementary Appendix).20,21 This algorithm previously showed very strong concordance with independent reviews in a phase 2 study”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > End Points and Assessments
What the sources say
- Not checked — no full text of the sourcecites [20] source
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [9] source
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Every source the paper cites for this claim was checked and supports it.
In the paper
“A phase 3 trial of bortezomib and dexamethasone, with or without daratumumab, met its primary end point at the interim analysis and showed a significantly higher rate of progression-free survival, with a 61% lower risk of progression or death in the daratumumab group than in the control group.18”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Supportedcites [18] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“After the implementation of guidelines from other studies of daratumumab regarding the management of infusion-related reactions, infusion-related reactions were consistent with daratumumab monotherapy 9,10 and combination therapy, 18,19,32 were mostly of grade 1 or 2, and usually occurred during the first infusion.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
What the sources say
- Not checked — no full text of the sourcecites [9] source
- Supportedcites [10] source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [18] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Could not verifycites [32] Chari A, 2015, Blood sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Response was assessed according to the Uniform Criteria Consensus recommendations of the International Myeloma Working Group.20,21”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
What the sources say
- Not checked — no full text of the sourcecites [20] source
- Supportedcites [21] source
The Response criteria section recommends using the IMWG uniform response criteria in clinical trials and says the panel endorsed their response definitions. The citation therefore supports the identification of the criteria used; it does not independently document how the citing study assessed response. (LLM, conf=0.93)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Daratumumab interferes with laboratory-based bloodcompatibility tests, including indirect Coombs' test, because of binding to CD38 on red cells.26”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
What the sources say
- Supportedcites [26] source
The Discussion says daratumumab interferes with blood compatibility testing because it binds directly to CD38 on red cells. The “DARA causes plasma panreactivity in vitro” section reports panreactivity at the antihuman globulin phase, supporting the reference to the indirect Coombs test. (LLM, conf=0.93)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab was associated with infusion-related reactions and a higher rate of neutropenia than the control therapy.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Daratumumab-associated infusion-related reactions occurred in 47.7% of the patients and were mostly of grade 1 or 2.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, in the time-toevent analysis of disease progression, a total of 148 events (in 44 patients [15.4%] in the daratumumab group vs. 104 [36.7%] in the control group) were observed (hazard ratio, 0.34; 95% CI, 0.23 to 0.48; P<0.001).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of patients with adverse events leading to the discontinuation of treatment was similar in the two groups: 6.7% in the daratumumab group and 7.8% in the control group.”
- Also stated in: § Patients who have very good partial responses · plain
“The rates of treatment discontinuation owing to adverse events were low and similar in the two groups.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Patients who have very good partial responses · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The treatment effect of daratumumab was consistent regardless of previous exposure to lenalidomide (a limitation being the relatively small number of patients with previous exposure to lenalidomide) and across all subgroups, including patients 65 years of age or older, those with disease that was refractory to proteasome inhibitors or the most recent line of therapy, those with International Stag”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although higher rates of neutropenia and infusion-related reactions (primarily during the first infusion) were observed with this combination than with lenalidomide and dexamethasone alone, these events did not result in higher rates of treatment discontinuation or death.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After continued treatment, responses deepened, with a rate of complete response or better that was twice as high with daratumumab as with the backbone regimen alone.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These reactions were mostly of grade 1 or 2; a total of 15 patients (5.3%) had grade 3 infusion reactions, and no patient had an event of grade 4 or 5.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedn = 15Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall response No. with response 261 211 -Rate -% (95% CI) 92.9 (89.2-95.6)76.4 (71.0-81.3)<0.001”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Serious adverse events were reported in 48.8% of the patients in the daratumumab group and in 42.0% of those in the control group, among which pneumonia was the most common (in 8.1% of the patients in the daratumumab group and in 8.5% of those in the control group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rate of infection of grade 3 or 4 was also slightly higher in the daratumumab group than in the control group (28.3% and 22.8%, respectively); the most common infection of grade 3 or 4 was pneumonia, which occurred at similar rates in the two groups.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common adverse events leading to death were acute kidney injury (in 0.4% of the patients in the daratumumab group and in 1.1% in the control group), septic shock (in 1.1% and 0.4%, respectively), and pneumonia (in 0.7% in each group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedn = 11Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“incidences of grade 3 or 4 diarrhea, fatigue, nausea, and dyspnea were slightly higher in the daratumumab group than in the control group.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Stringent complete response § 51 (18.1) 20 (7.2) -”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Efficacy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The incidence of daratumumab infusionrelated reactions of any grade was 47.7%, with 92% of the reactions occurring during the first infusion.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common adverse events (in ≥1% of the patients in either group) that led to the discontinuation of treatment included pneumonia (in 1.1% of the patients in the daratumumab group and in 0.7% of those in the control group), pulmonary embolism (in 1.1% in the control group), and deterioration in general physical health (in 1.1% in the daratumumab group).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Despite higher rates of neutropenia in the daratumumab group, the rate of infection of grade 3 or 4 was only slightly higher in the daratumumab group than in the control group (28% vs. 23%).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As in the CASTOR trial, 18 the addition of daratumumab to the backbone regimen in our trial resulted in a significantly higher rate of overall response, deeper responses, and longer duration of response.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common infusion-related reactions were cough (in 8.5% of the patients), dyspnea (in 8.5%), and vomiting (in 5.7%) (Table S5 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Table 3. Most Common Adverse Events during Treatment in the Safety Population.*
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“A phase 1-2 study of daratumumab, lena-lidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma showed that this combination provided therapeutic benefits, no dose-limiting toxic effects, and an 81% rate of overall response, including a 25% rate of stringent complete response”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The group-sequential design had one planned interim analysis to evaluate the primary end point.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Statistical Analysis
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“he incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has improved outcomes in patients with multiple myeloma over the past 10 years, [1][2][3]”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [1][2][3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was approved by the independent ethics committee or institutional review board at each site before the initiation of the trial.Patients provided written informed consent, and the trial was conducted in accordance with the principles of the Declaration of Helsinki and current International Conference on Harmonisation Good Clinical Practice guidelines.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Trial Design
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“An independent data and safety monitoring committee was established to periodically review unblinded safety data.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > End Points and Assessments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“At 18 months, the rate of progression-free survival was 72%, and the rate of overall survival was 90%.19”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Abstract
What the sources say
- Not matchedcites [19] Plesner T, Blood
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The most common reasons for the discontinuation of treatment were progressive disease (in 14.1% of the patients in the daratumumab group vs. 34.2% of those in the control group) and adverse events (in 6.7% vs. 8.2%) (Fig. S2 in the Supplementary Appendix).”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients and Treatment
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We calculated that approximately 560 patients with 295 events (disease progression or death) would be needed to provide the trial with 85% power to detect a 30% lower risk of disease progression or death (hazard ratio, 0.70), using a log-rank test, with an overall two-sided significance level of 0.05.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Statistical Analysis
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This suggests that results below the threshold for minimal residual disease also should be a treatment goal in the context of relapsed or refractory disease.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Figure 2. Prespecified Subgroup Analyses.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Shown are the results of the Kaplan-Meier analysis of progression-free survival among patients in the intention-totreat population, which included all patients who underwent randomization.”
§ Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma > Patients who have very good partial responses
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
The paper relies on this without support.
Relapse can occur even after standard complete remission in the context of first-line therapy.
“Relapse can occur even after standard complete remission in the context of first-line therapy, and studies are therefore evaluating deeper responses in a category termed “minimal residual disease-negative””
The paper relies on this without support.
The combination of lenalidomide and dexamethasone is an appropriate standard control regimen for patients with relapsed or refractory multiple myeloma who have received one or more previous lines of therapy.
“we randomly assigned 569 patients with multiple myeloma who had received one or more previous lines of therapy to receive lenalidomide and dexamethasone either alone (control group) or in combination with daratumumab (daratumumab group).”
The paper relies on this without support.
The open-label design does not bias the assessment of progression-free survival.
“In this randomized, open-label, multicenter, phase 3 trial, we assigned patients who had relapsed or refractory multiple myeloma and had received one or more lines of previous therapy to receive either daratumumab, lenalidomide, and dexamethasone (daratumumab group) or lenalidomide and dexamethasone (control group).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recently approved monoclonal antibody, daratumumab, which targets CD38 (a receptor highly expressed on myeloma cells), has become a favorite for later line induction regimens [35,36].”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [36]
Experimental — accuracy not yet measuredIn the citing paper
“Response rates to single-agent lenalidomide have consistently been surpassed by those achieved with doublet or triplet combinations, which has been taken as evidence for synergistic activity of this agent with other anti-myeloma agents48.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Control-group adverse-event discontinuation rates differ
MinorThe results give 8.2% of control-group patients as discontinuing treatment because of adverse events, but the safety section gives 7.8% for adverse events leading to treatment discontinuation. The text does not explain the difference.
“The most common reasons for the discontinuation of treatment were progressive disease (in 14.1% of the patients in the daratumumab group vs. 34.2% of those in the control group) and adverse events (in 6.7% vs. 8.2%)”
“The percentage of patients with adverse events leading to the discontinuation of treatment was similar in the two groups: 6.7% in the daratumumab group and 7.8% in the control group.”
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationKumar, S. K., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2013) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,383
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Krejcik J, Blood
- Plesner T, Blood
Cited by
Sorted by citations
Items 901–1,000 of 1,433
Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?
Cooke, R. E., Koldej, R. M., & Ritchie, D. (2019) · Journal of Oncology · doi:10.1155/2019/2186494 · Cited by 5
Oriol, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1744432 · Cited by 6
Self-citationJung, J., Choi, Y. S., Lee, J. H., Lee, J. H., Kim, S., Park, Y., Lee, S.-S., Do, Y. R., Jo, J.-C., Lee, J., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02869-y · Cited by 7
Self-citationModern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients
Premkumar, V. J., Bhutani, D., & Lentzsch, S. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.06.023 · Cited by 7
Antibody‐based immunotherapy for treatment of immunoglobulin light‐chain amyloidosis
Parrondo, R. D., Majeed, U., & Sher, T. (2020) · British Journal of Haematology · doi:10.1111/bjh.16697 · Cited by 6
“gov Identifier: NCT02136134) trials, daratumumab was combined with lenalidomide/dexamethasone and bortezomib/dexamethasone, respectively, achieving deep and durable responses in relapsed/refractory MM (RRMM).(27,28) The plasma cell clone in AL amyloidosis also expresses CD38 and high CD38 expression has been found to…”
MethodChen, M., Zhao, L., Yao, F., & Yang, X. D. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13819 · Cited by 5
“Dara has an acceptable safety profile as monotherapy,(1,2) combinational therapy with proteasome inhibitors (PI) bortezomib,(3) and immunomodulatory drugs.(4) The common adverse events of Dara are infusion-related reactions.”
BackgroundRisk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies
Andreescu, M. (2023) · Life · doi:10.3390/life13061272 · Cited by 5
“Several adverse events, including neutropenia, thrombocytopenia, and anemia, have been recorded with the use of daratumumab [74].”
BackgroundBarilà, G., Quaglia, F. M., Furlan, A., Pescosta, N., Bonalumi, A., Marcon, C., Pascarella, A., Tinelli, M., March, E. D., Liço, A., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05443-8 · Cited by 5
Goudarzi, Z., Shahtaheri, R. S., Najafpour, Z., et al. (2024) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-024-00525-4 · Cited by 5
“Combined with therapies including Bortezomib/dexamethasone (Vd; CASTOR trial) [21] and Lenalidomide/ dexamethasone (Rd; POLLUX trial) [22], this drug significantly prolonged PFS and OS in patients with RRMM.”
MethodLee, J. H., Choi, J., Min, C., Park, S., Jo, J., Lee, Y. J., Kim, J. S., Eom, H., Jung, J., Moon, J. H., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285534 · Cited by 6
Self-citationLim, S., Reynolds, J., Quach, H., Hutchinson, A., Kerridge, I., Janowski, W., Bergin, K., & Spencer, A. G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19578 · Cited by 5
Koh, M. Y., Chung, T., Tang, N. X. N., Toh, S. H. M., Zhou, J., Tan, T. K., Chen, L., Chng, W. J., & Teoh, P. J. (2024) · Blood · doi:10.1182/blood.2024024429 · Cited by 6
Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?
Vijjhalwar, R., Kannan, A., Fuentes-Lacouture, M. C., & Ramasamy, K. (2025) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-025-02008-9 · Cited by 6
“Lenalidomide combined with dexamethasone achieved an overall response rate (ORR) of 76%, which increases to 93% when daratumumab is added, as demonstrated in studies of the daratumumab, lenalidomide, and dexamethasone (DRd) regimen [41, 42 ].”
InfluentialSociety of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma
Richter, J. R., & Jagannath, S. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.09.003 · Cited by 5
Daratumumab and its efficacy in refractory myeloma with anemia
Bagal, B. P., Bondili, S. K., Nandhana, R., Gokarn, A. G., Bonda, A., & Sengar, M. (2020) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_283_20 · Cited by 5
Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma
Ovejero, S., & Moreaux, J. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00034 · Cited by 5
“The first clinical trials for DARA have provided encouraging results about its use alone [101] or together with other drugs [102-104].”
BackgroundDaratumumab and Lenalidomide Maintenance Guided by Minimal Residual Disease in Multiple Myeloma
Dhakal, B., & Usmani, S. Z. (2021) · The Hematologist · doi:10.1182/hem.v18.6.202166 · Cited by 5
Self-citationFazio, F., Franceschini, L., Tomarchio, V., Rago, A., Garzia, M., Cupelli, L., Bongarzoni, V., Andriani, A., Gumenyuk, S., Tafuri, A., et al. (2022) · eJHaem · doi:10.1002/jha2.359 · Cited by 5
“Specifically, the phase III POLLUX trial, with primary endpoint PFS, compared DRd versus Rd in 569 pts with RRMMwho had previously received ≥1 line of therapy [18].”
BackgroundMethodMizuguchi, M., Okamoto, Y., Yagi, H., Kagawa, K., Sekimoto, E., Shibata, H., Shigekiyo, T., & Ozaki, S. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03541-x · Cited by 5
Pomalidomide combinations are a safe and effective option after daratumumab failure
Brioli, A., Gengenbach, L., Mancuso, K., Binder, M., Ernst, T., Heidel, F. H., Stauch, T., Zamagni, E., Hilgendorf, I., Hochhaus, A., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04637-x · Cited by 5
Horigome, Y., Iino, M., Harazaki, Y., Kobayashi, T., Handa, H., Hiramatsu, Y., Kuroi, T., Tanimoto, K., Matsue, K., Abe, M., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05428-7 · Cited by 5
“…IRd therapy would have a similar median PFS (the primary outcome) as reported for Rd therapy in Japanese patients with RRMM (15–18 months) [10, 16–18] and that there would be no difference in the relative effectiveness of IRd versus Rd in this study versus the TOURMALINE-MM1 study [10], we…”
ResultCurrent status of bispecific antibodies and CAR-T therapies in multiple myeloma
Szlasa, W., & Dybko, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112043 · Cited by 6
Voorhees, P. M., Suman, V. J., Efebera, Y. A., Raje, N. S., Tuchman, S. A., Valdes, C. R., Laubach, J. P., Bova‐Solem, M., Carlisle, D., Usmani, S. Z., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013623 · Cited by 6
Self-citationRujirachaivej, P., Siriboonpiputtana, T., Choomee, K., Supimon, K., Sangsuwannukul, T., Songprakhon, P., Natungnuy, K., Luangwattananun, P., Yuti, P., Junking, M., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-05923-z · Cited by 7
“Noteworthy progress has been achieved in MM treatment with the introduction of novel agents such as proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies (mAbs), thus enhancing the life expectancy of MM patients [4].”
Approvals in 2016: cost–benefit challenges of new anticancer agents
Savage, P. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.12 · Cited by 5
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma
Zannetti, B. A., Tacchetti, P., Pantani, L., Gamberi, B., Tosi, P., Rocchi, S., Cellini, C., Ronconi, S., Pezzi, A., Mancuso, K., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3140-5 · Cited by 6
Therapy Sequencing Strategies in Multiple Myeloma: Who, What and Why?
Costello, C. L., & Mikhael, J. R. (2017) · Future Oncology · doi:10.2217/fon-2017-0493 · Cited by 5
Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?
Musto, P. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0097 · Cited by 5
“Both CASTOR [15, 16] and POLLUX [17, 18] studies have recently been updated.”
BackgroundGlobal Approaches in Myeloma: Critical Trials That May Change Practice
Moreau, P., & Touzeau, C. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200841 · Cited by 5
Self-citationChehab, S., Zhang, C., Panjic, E. H., Chen, Z., Kaufman, J. L., Lonial, S., Nooka, A. K., & Harvey, R. D. (2018) · Cancer · doi:10.1002/cncr.31746 · Cited by 5
Alahmadi, M. D., Masih‐Khan, E., Atenafu, E. G., Chen, C. I., Kukreti, V., Tiedemann, R. E., Trudel, S., & Reece, D. E. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.007 · Cited by 5
Self-citationTherapy for relapsed multiple myeloma
Aljama, M. A., Sidiqi, M. H., & Dingli, D. (2018) · Panminerva Medica · doi:10.23736/s0031-0808.18.03542-5 · Cited by 5
Hradská, K., Kaščák, M., Hájek, R., & Jelı́nek, T. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1733405 · Cited by 5
Natural History and Prognostic Factors at First Relapse in Multiple Myeloma
Wang, C., Soekojo, C. Y., Mel, S. D., Ooi, M. G. M., Chen, Y., Goh, A. Z. K., Nagarajan, C., & Chng, W. J. (2020) · Cancers · doi:10.3390/cancers12071759 · Cited by 5
“Of note, the unprecedented hazard ratios of PFS achieved by adding daratumumab triggered great enthusiasm to consider a daratumumab-based regimen as the preferred choice at first relapse [11,12].”
BackgroundHow I Treat Relapsed and/or Refractory Multiple Myeloma
Lee, H. C., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.8955 · Cited by 5
Scheid, C., Blau, I. W., Sellner, L., Ratsch, B. A., & Basic, E. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13523 · Cited by 5
Evolution or revolution in multiple myeloma therapy and the role of the UK
Cook, G., & Morris, C. T. C. M. (2020) · British Journal of Haematology · doi:10.1111/bjh.17148 · Cited by 5
Gordan, L., Chang, M. M., Lafeuille, M., Romdhani, H., Paramasivam, F., Maiese, E. M., & McKay, C. (2021) · Drugs - Real World Outcomes · doi:10.1007/s40801-020-00226-3 · Cited by 5
“9%) [11, 14], and highest in trials of daratumumab-containing combination therapies in newly diagnosed patients (ORRs 90.”
BackgroundCao, C., Zhou, X., & Ma, Q. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.797 · Cited by 5
Mohan, M., Maatman, T. C., & Schinke, C. (2021) · Cancers · doi:10.3390/cancers13194909 · Cited by 5
“In the phase III POLLUX study conducted in RRMM patients, DRd lead to a 63% lower risk of progres‐ sion or death compared to the control arm of Rd [39].”
ResultIsatuximab plus Pomalidomide and Dexamethasone in a Patient with Dialysis-Dependent Multiple Myeloma
Takakuwa, T., Ohta, K., Sogabe, N., et al. (2021) · Chemotherapy · doi:10.1159/000519783 · Cited by 5
Current and prospective antibody-based therapies in multiple myeloma
Bryer, E. J., DeStefano, C. B., & Kazandjian, D. G. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.11.002 · Cited by 6
Wang, J., Arroyo-Suárez, R., Dasari, S., Sekaran, K., & Tse, W. W. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2038376 · Cited by 5
“In this study, using individual participant data from three phase 3 clinical trials, POLLUX [11], CASTOR [12], and MAIA [13] – all comparing daratumumab-based triplet therapies with doublet conventional regimens – we studied survival outcomes based on early or late responses to daratumumab, and identified factors asso…”
MethodMcCurdy, A. B. R., Venner, C. P., Masih‐Khan, E., Louzada, M., LeBlanc, R., Sébag, M., Song, K., Jimenez-Zepeda, V. H., Kotb, R. R., Kardjadj, M., et al. (2022) · Current Oncology · doi:10.3390/curroncol29030132 · Cited by 5
Self-citationBarth, P. M., Vale, C. A., Chambers, A. B., & Reagan, J. L. (2018) · Future Oncology · doi:10.2217/fon-2017-0722 · Cited by 5
Huang, L., Wong, S. W. K., Andreadis, C. B., & Olin, R. L. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0778-2 · Cited by 5
Isa, R., Uoshima, N., Takahashi, R., Nakano-Akamatsu, S., Kawata, E., Kaneko, H., Shimura, K., Kamitsuji, Y., Takimoto‐Shimomura, T., Mizutani, S., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03859-9 · Cited by 5
Fukuoka Blood and Marrow Transplantation Group, Mori, Y., Choi, I., Yoshimoto, G., Muta, T., Yamasaki, S., Tanimoto, K., Kamimura, T., Iwasaki, H., Ogawa, R., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02833-w · Cited by 5
The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
Bobin, A., Gardeney, H., Sabirou, F., Gruchet, C., Lévy, A., Nsiala, L., Cailly, L., Tomowiak, C., Diaz, J. M. T., Guidez, S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00676 · Cited by 5
“Interestingly, as seen in the first publication (19), the patients who benefited the most from the association dara-Rd were the ≥75 yo group (HR 0.”
BackgroundLee, H. S., Kım, K., Lee, J., Yoon, S., Bang, S., Kim, J. S., Eom, H., Yoon, D. H., Lee, Y., Shin, H., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02988-6 · Cited by 6
Self-citationXavier, F. D., Ferreira, F. S. B., & Abreu, R. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27819 · Cited by 5
“In the case of biochemical relapse, especially during maintenance therapy, increasing the current drug dose and subsequently adding another agent is a recommended strategy [45].”
Duarte, P. J., Schutz, N. P., Ochoa, P. A., Yantorno, S., Orlando, S., Lopresti, S., Zabaljauregui, S., Aizpurua, F., Shanley, C. M., Giannini, E., et al. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1886073 · Cited by 5
“21 months, in contrast to the POLLUX phase 3 clinical trial [3], where the PFS was 45 months in its last update [17].”
ResultOzaki, S., Handa, H., Koiso, H., Saitoh, T., Sunami, K., Ishida, T., Suzuki, K., Narita, T., Iida, S., Nakamura, Y., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03668-6 · Cited by 5
Self-citationBapatla, A., Kaul, A., Dhalla, P. S., et al. (2021) · Cureus · doi:10.7759/cureus.15440 · Cited by 5
“Daratumumab-based combinations showed significant benefit in phase three and phase one/two clinical trials [11-13].”
BackgroundResultInfluentialTreatment of double-refractory multiple myeloma
Семочкин, С. В. (2021) · Oncohematology · doi:10.17650/1818-8346-2021-16-3-58-73 · Cited by 5
Suzuki, K., Nishiwaki, K., Gunji, T., Katori, M., Masuoka, H., & Yano, S. (2020) · Cancer Medicine · doi:10.1002/cam4.2828 · Cited by 5
Self-citationWu, Y., Wu, X., Liu, X., Zheng, X. Y., Deng, J., & Gong, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08588-9 · Cited by 6
“…glycoprotein of MM cells such as elotuzumab improved the prognosis of MM patients when administered in combination with proteasome inhibitors or Dimopoulos(2016) POLLUX Dimopoulos(2018) POLLUX III 569 T:daratumumab16mg/kg + lenalidomide25mg + dexamethasone40mg C:lenalidomide25mg +…”
BackgroundInfusion Reactions With Monoclonal Antibody Therapy in Myeloma: Learning From Experience
Reece, D. E., & Phillips, M. J. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00377 · Cited by 5
Self-citationEvolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions
Goldsmith, S. R., & Vij, R. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00210 · Cited by 5
Molecular and immunological determinants of long-term survival in multiple myeloma
Kasomva, K., Yadav, K., Janz, S., Dhakal, B., & Rao, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016829 · Cited by 4
Orgueira, A. M., Perez, M. S. G., D’Agostino, M., Cairns, D. A., Larocca, A., Palacios, J. J. L., Wester, R., Bertsch, U., Waage, A., Zamagni, E., et al. (2025) · HemaSphere · doi:10.1002/hem3.70228 · Cited by 6
“19,38 The models maintained strong predictive accuracy in this population, even among patients receiving daratumumab ‐ based regimens, highlighting their applicability across different disease stages and treatment settings.”
Self-citationAndré, A., Montes, L., Roos‐Weil, D., Frenzel, L., Vignon, M., Chalopin, T., Debureaux, P.-É., Talbot, A., Farge, A., Jardin, F., et al. (2024) · HemaSphere · doi:10.1002/hem3.106 · Cited by 5
Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency
Bladé, J., Rosiñol, L., Cibeira, M. T., & de Larrea, C. F. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6419 · Cited by 4
Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
Barilà, G., Pavan, L., Vedovato, S., Berno, T., Schirico, M. L., Febbo, M. A., Teramo, A., Calabretto, G., Vicenzetto, C., Gasparini, V. R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682658 · Cited by 4
“Median Age (years) 62 (24-93) 67 (35-85) 69 (39-90) 65 (38-87)”
Vincent, L., Gras, L. A., Céballos, P., Finke, J., Passweg, J. R., Harel, S., Rosiñol, L., Minnema, M. C., Teipel, R., van Doesum, J. A., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01560-y · Cited by 4
Maisnar, V., Pour, L., Špıčka, I., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.11.001 · Cited by 4
Simultaneous quantification of thalidomide, lenalidomide and pomadomide in plasma by LC-MS/MS
Wang, B., Qiang, W., Yi, J., Gao, S., Meng, B., Mu, Y., Wang, B., Wang, Z., & Tao, X. (2023) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2023.107250 · Cited by 7
Novellis, D. D., Fontana, R., Palmieri, S., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-01001-4 · Cited by 4
“In our cohort of 65% newly diagnosed patients and 35% of patients with RR/MM, IRR rate was 4%, similar to that reported in pivotal PLEIADES study and significantly lower than those ) [8, 9, 19].”
ResultExperience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
Tekinalp, A., Gedük, A., Akdeniz, A., et al. (2023) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2023.2023.0029 · Cited by 4
Li, K., Shuping, S., Chang, S., Yiyue, C., Qinyu, X., Zhang, T., & Wu, B. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2389 · Cited by 4
Tso, A. C. Y., Chng, W. J., Goh, Y. T., Ooi, M. G. M., Chen, Y., Nagarajan, C., Tan, D. C. L., Acharyya, S., & Ong, K. H. (2024) · Clinical Hematology International · doi:10.46989/001c.124362 · Cited by 4
Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes
Petrucci, M. T., Bringhen, S., Cerezo, C. E., Mendes, J., & Armeni, P. (2024) · Hematology · doi:10.1080/16078454.2024.2432815 · Cited by 4
García‐Guiñón, A., Charry, P. A., Lorenzo, M.-J. J., Sarrà, J., Delgado, I., de la Torre, L. S., Santaliestra, M., García‐Pintos, M., Gonzalez, Y., Senín, A., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06240-1 · Cited by 5
“In patients with relapsed / refractory MM (RRMM), the second-line therapy should include a lenalidomide plus dexamethasone (Rd)-based regimen [12–14].”
Home‐Based Daratumumab in Patients With Multiple Myeloma
Rosenberg, T., Kirkegaard, J., Gundesen, M. T., Rasmussen, M. K., Dieperink, K. B., & Lund, T. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14409 · Cited by 5
Should minimal residual disease negativity not be the end point of myeloma therapy?
Sonneveld, P. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017000109 · Cited by 4
Treatment of Multiple Myeloma With Daratumumab in a Kidney Transplant Patient
Yang, D., Agrawal, N., Marcus, C. B., Roy, N., Richards, K. R., Nahas, M. R., & Cardarelli, F. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001024 · Cited by 4
Tan, T., Hong, Y., Li, S., Yu, J., Sung, Y.-C., Wang, P.-N., & Teng, C. J. (2020) · The Chinese Journal of Physiology · doi:10.4103/cjp.cjp_68_20 · Cited by 4
Steinhardt, M., Zhou, X., Krummenast, F., Meckel, K., Nickel, K., Böckle, D., Messerschmidt, J., Knorz, S., Dierks, A., Heidemeier, A., et al. (2020) · International Journal of Immunopathology and Pharmacology · doi:10.1177/2058738420980258 · Cited by 4
Hung, Y.-C., Gau, J., Huang, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695410 · Cited by 4
“Currently, lenalidomide with dexamethasone (4, 5) or lenalidomide-dexamethasonebased regimens (6, 7) are one of the primary treatment options for MM patients who are refractory to or experience relapse from bortezomib-based induction therapies in Taiwan.”
BackgroundHughes, D., Henshaw, L., Blevins, F., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.03.003 · Cited by 4
Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma
Chu, T.-H., Jung, S., Kım, K., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04776-0 · Cited by 4
“Daratumumab in combination with bortezomib or lenalidomide improved the PFS of patients with relapsed and refractory MM [22, 23], although plasmacytoma at relapse was not evaluated.”
BackgroundMele, G., Cascavilla, N., Renzo, N. D., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04857-0 · Cited by 4
“The POLLUX (NCT02076009) [3] and CASTOR (NCT02136134) [2] phase 3 trials, comparing the use of daratumumab with lenalidomide or bortezomib plus dexamethasone against the ‘standard-of-care’ regimens, respectively, showed exceptional outcomes with daratumumab-based combinations.”
BackgroundInfluentialMeasurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?
Caetano, J., Barahona, F., Lúcio, P., & Joao, C. M. (2022) · Hemato · doi:10.3390/hemato3030027 · Cited by 4
“The POLLUX [42] and CASTOR [151] trials assessed MRD by NGS (sensitivity threshold of 10 − 5 ) in patients at suspected CR, following confirmed CR (3 and 6 months in POLLUX; 6 and 12 months in CASTOR), and every 12 months after CR.”
InfluentialShimazu, Y., Kanda, J., Kaneko, H., Imada, K., Yamamura, R., Kosugi, S., Shimura, Y., Ito, T., Fuchida, S., Uchiyama, H., et al. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221142487 · Cited by 4
“From these results, we proposed two new models to predict a durable effect (longer TTNT) under the DLd regimen by classifying the patients into three categories based on either (1) monocyte counts and B2MG (model 1) or (2) WBC counts and B2MG (model 2).”
MethodEsposito, P. B., Picciotto, D., Costigliolo, F., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1266172 · Cited by 4
Supportive Therapy in Multiple Myeloma: Practical Recommendations
Solovev, M. V., Соловьева, М. В., & Mendeleeva, L. P. (2023) · Clinical oncohematology · doi:10.21320/2500-2139-2023-16-4-426-448 · Cited by 4
Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement
Jang, S. Y., Byun, J. M., Yoon, S., et al. (2023) · Blood Research · doi:10.5045/br.2023.2023194 · Cited by 4
Self-citationAlmansour, S. A., Alqudah, M. A. Y., Abuhelwa, Z., Al-Shamsi, H. O., Semreen, M. H., Bustanji, Y. K., Soare, N. C., McKinnon, R. A., Sorich, M. J., Hopkins, A. M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-48640-1 · Cited by 4
“Furthermore, in MM mouse models, the presence of Prevotella heparinolytica in the gut influenced the immune system through T-helper 17 cells, which causes T cells to migrate to the myeloma environment and fuel tumor progression through IL-17 production 29 .”
BackgroundWeisel, K. C., Dimopoulos, M. A., Beksaç, M., Leleu, X. P., Richter, J. R., Heeg, B. M. S., Patel, S. H., Majer, I. M., McFadden, I., & Mikhael, J. R. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2300051 · Cited by 4
Self-citationDima, D., Mansour, R. A., Davis, J. A., Minchak, M., Goel, U., Atallah, R., Logan, E., Tabak, C., Rashid, A., Ahmed, N., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14193 · Cited by 5
Immunotherapeutic Approaches in Cancer
Keshavarz‐Fathi, M., & Rezaei, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814039-0.00002-3 · Cited by 6
LeBlanc, R., Song, K., White, D. J., Christofides, A., & Doucette, S. (2019) · Current Oncology · doi:10.3747/co.26.5565 · Cited by 4
A pharmacist’s review of the treatment of systemic light chain amyloidosis
Hughes, D., Staron, A., & Sanchorawala, V. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220963534 · Cited by 4
Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review
Ismail, N. H., Mussa, A., Al‐Khreisat, M. J., Yusoff, S. M., Husin, A., & Johan, M. F. (2023) · Diagnostics · doi:10.3390/diagnostics13142328 · Cited by 5
The treatment of multiple myeloma in an era of precision medicine
Kint, N., Vlayen, S., & Delforge, M. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1606672 · Cited by 4
“Based on the increased prognostic importance of MRD status, many ongoing clinical studies include MRD status in their analysis [54].”
BackgroundNakamura, F., & Nasu, R. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03711-0 · Cited by 4
“Although neutropenia was more common in daratumumab triplet therapy, the addition of daratumumab did not significantly increase documented infections and treatment discontinuation [3, 4].”
BackgroundAL patients don’t dare go without dara
Dispenzieri, A. A. (2020) · Blood · doi:10.1182/blood.2020005436 · Cited by 4
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma
Paul, B. A., Atrash, S., Bhutani, M., Voorhees, P. M., Hamadeh, I. S., & Usmani, S. Z. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1795829 · Cited by 4
Self-citationKunacheewa, C., Feng, L., Manasanch, E. E., Bashir, Q., Patel, K. K., Mehta, R. S., Kaufman, G. P., Srour, S. A., Saini, N., Iyer, S. P., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17393 · Cited by 4
“of del 17p, t(4;14), and/or t(14;16), received LEN-combination (39%) versus LEN-monotherapy (12%) maintenance.”
Self-citationKlein, C. (2018) · MDPI eBooks · doi:10.3390/books978-3-03842-876-3 · Cited by 4
Metadata
- Authors
- Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., Plesner, T., Yoon, S.-S., Ben Yehuda, D., Richardson, P. G., Goldschmidt, H., Reece, D., Lisby, S., Khokhar, N. Z., O’Rourke, L., Chiu, C., Qin, X., Guckert, M., Ahmadi, T., & Moreau, P.
- Affiliations
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-10-06
- Volume
- 375
- Issue
- 14
- Pages
- 1319-1331
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2528329272
- Cited by
- 1,445
- References
- 32
- Citations by year
- 2026: 50 · 2025: 78 · 2024: 78 · 2023: 108 · 2022: 138 · 2021: 221 · 2020: 236 · 2019: 175 · 2018: 193 · 2017: 148 · 2016: 15
- FWCI
- 168.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Spectrum Pharmaceuticals
- Celgene
- Incyte
- Otsuka Pharmaceutical
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- daratumumab, lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, minimal residual disease, complete response, neutropenia, thrombocytopenia, adverse events, monoclonal antibody therapy, combination therapy, overall response rate, safety and tolerability
- MeSH terms
- Lenalidomide, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Disease-Free Survival, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
